Clinical and molecular determinants of response to maintenance olaparib for primary and recurrent epithelial ovarian carcinoma
LT response to olaparib for primary maintenance is common, and more frequently observed in patients with a complete response to platinum-based chemotherapy. BRCA2 mutations conferred exceptional benefit to olaparib. Durable benefit was more commonly observed in patient's receiving frontline maintenance olaparib.
Authors
- Lauren Montemorano
- Kharmen Bharucha (ORCID: https://orcid.org/0000-0003-0300-4309)
- Lisa Barroilhet (ORCID: https://orcid.org/0000-0001-9315-2414)
- Matthew K. Wagar (ORCID: https://orcid.org/0000-0003-2300-404X)
- Laura Huffman
- Amy L. Godecker (ORCID: https://orcid.org/0000-0001-8681-7385)
Institutions
- University of Wisconsin–Madison (US)
Publication Details
- Journal
- Clinical & Translational Oncology
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1007/s12094-025-04105-7
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00